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Peroxisome proliferator-activated receptor δ (PPARδ,a l s ok n o w na sP P A R β) has ubiquitous distribution and extensive biological
functions. The reproductive function of PPARδ was ﬁrst revealed in the uterus at the implantation site. Since then, PPARδ and
its ligand have been discovered in all reproductive tissues, including the gametes and the preimplantation embryos. PPARδ in
preimplantation embryos is normally activated by oviduct-derived PPARδ ligand. PPARδ activation is associated with an increase
in embryonic cell proliferation and a decrease in programmed cell death (apoptosis). On the other hand, the role of PPARδ and its
ligand in gamete formation and function is less well understood. This review will summarize the reproductive functions of PPARδ
and project its potential applications in assisted reproductive technology.
Copyright © 2008 Jaou-Chen Huang. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Assisted reproduction uses a spectrum of technologies to
enhance fertility. In vitro fertilization (IVF) is the most
advanced and most sophisticated assisted reproductive tech-
nology (ART). Since the ﬁrst “IVF baby”, Louise Brown,
was born in 1978, IVF has gradually been accepted by
the general public. Nowadays, IVF is a routine proce-
dure to treat the infertile couples. Recent data shows
more than 45000 IVF babies were born in the US each
year (http://www.cdc.gov/ART/ART2005/section1.htm)a n d
there are more than three millions “IVF babies” in the world
(http://news.bbc.co.uk/1/hi/health/5101684.stm).
Compared with embryos in natural pregnancies,
IVF embryos have low implantation potential (about
15–20% per embryo, http://apps.nccd.cdc.gov/ART2005/
nation05.asp). In order to increase IVF success, it is
common to transfer two or more embryos to the uterus.
This practice not only increases the odds of pregnancy
but also increases the chance of multiple pregnancy.
Compared with natural conception, IVF pregnancies are
thirty times more likely to be multiple (32% versus 1%,
http://www.cdc.gov/ART/ART2005/sect2 ﬁg5-15.htm#Figu-
re 8). Furthermore, 13% of the IVF multiple pregnancies
are “high-order” multiple pregnancies, that is, triplets or
more. These pregnancies are prone to develop obstetrical
complications and pose great risks to mothers and infants.
As a result, some infants suﬀer short-term complications
and life-long sequels. Therefore, one of the most urgent
tasks in ART is to enhance the implantation potential of
IVF embryos so that transferring single embryo yields an
acceptable chance of success.
It has long been observed that, compared with in vivo
embryos, embryos cultured in simple media develop at
a slower pace [1, 2] and have more apoptosis [3]. It is
generally accepted that, compared with in vivo embryos,
IVF embryos are in a less optimal environment—they
are not in the supportive and protective environment of
the oviduct. As a result, IVF embryos do not develop to
their full potential and do not implant as well as their
in vivo counterparts. It has been proposed that modifying
embryo culture conditions, making them similar to those
of the oviduct, may improve embryo development and
enhance IVF success. Recent reports show embryos express2 PPAR Research
PPARδ and that PPARδ activation by oviduct-derived ligand
enhances embryo development and implantation (more
below). Thus PPARδ is a novel pathway that could be
exploited to enhance ART outcome. This article will review
the current literature regarding PPARδ and reproduction
and outline the potential applications of its ligands in
ART. Because PPARδ interacts with PPARα and -γ,r e l e v a n t
information regarding PPARα and -γ will also be provided.
2. PPARS AND THEIR LIGANDS
Peroxisomes are organelles in eukaryotes that participate
in fatty acid oxidation. In 1990, the ﬁrst PPAR (PPARα)
was discovered in the mouse [4]. Two years later, PPARα
and two additional PPAR isotypes, PPARβ (also known
as PPARδ)a n dP P A R γ, were discovered in the Xenopus
[5]. Subsequently, all three isotypes were found in mouse
and many species including human. PPARδ was originally
discovered in a human osteosarcoma cell line [6] and later
found to be the human homolog of PPARβ in the Xenopus.
PPARs are ligand-activated transcription factors. They
form heterodimers with another nuclear receptor, retinoid X
receptor (RXR), which also has three isotypes: RXRα, β,a n d
γ [7].ThefunctionsofPPAR-RXRcomplexesaredetermined
by PPAR isotypes. Although either PPAR or RXR ligand
can activate PPAR-RXR complexes, simultaneous PPAR and
RXR binding yields more potent activities [8]. Whereas
PPARα and PPARγ activate genes related to glucose and lipid
metabolism, only a few genes are reported to be directly
regulated by PPARδ.P P A R δ reportedly upregulates PDK1,
ILK [9] and 14-3-3ε [10], and downregulates PTEN [9]a n d
11 beta hydroxysteroid dehydrogenase type 2 gene [11]. The
functions of these genes, unlike those regulated by PPARα
and PPARγ, are not limited to energy homeostasis. They
include carbohydrate homeostasis (PDK1), cell migration,
proliferation and adhesions (ILK), signal transduction (ILK)
and its modulation (14-3-3ε) and, ﬁnally, tumor suppression
(PTEN).
Unlike PPARα and PPARγ, the outcome of PPARδ
activation is not limited to the transcriptional activities
of genes directly regulated by PPARδ because PPARδ also
modulates the transcriptional activities of PPARα,P P A R γ,
other nuclear receptors (such as estrogen receptor), and
BCL-6 (a transcriptional repressor). A recent report shows
thatbindingofPPARδ byitsligandallowsfulltranscriptional
activities of PPARα and PPARγ, which is normally inhibited
by nonliganded PPARδ [12]. In addition, binding of PPARδ
by its ligand releases a transcription repressor BCL-6 [13]
which targets a group of genes with diverse activities
including transcription regulation (n = 18), protein binding
(n = 11), signal transduction (n = 10), catalysis (n =
8), structural molecule activity (n = 3), enzyme activity
regulation (n = 3), protein transportation (n = 2), cell
movement (n = 2), chaperone (n = 1), and unknown
function (n = 3) [14]. Thus PPARδ interacts with an
extensive array of intracellular proteins to regulate cellular
functions.
A diverse group of chemicals including hypolipidemic
drugs, herbicides, and industrial plasticizers causes liver
tumors in the rodents. They induce peroxisome proliferation
and led to the discovery of PPARα [4]. Fatty acids, particu-
larlytheunsaturatedfattyacids,andcertaineicosanoidsbind
to PPARα,- γ,a n d- δ with varying aﬃnities [8, 15]. Although
all PPAR isotypes bind to unsaturated fatty acids, PPARα
has the highest aﬃnity. Eicosanoids from the lipoxygenase
pathway (such as leukotrienes and hydroxyeicosatetraenoic
acids—HETEs) and the cyclooxygenase pathway (such as
prostaglandins—PGs) bind to PPARs: leukotriene B4 and
8(S)-HETE are PPARα ligand, 15-deoxy-Δ12,14-PGJ2 (a
PGD2 derivative) is a PPARγ ligand, and PGI2 is a PPARδ
ligand [15]. In addition to the natural ligands, PPARs
also respond to synthetic ligands. Some of the synthetic
PPAR ligands are currently used to treat metabolic diseases:
ﬁbrates, which bind to PPARα, are hypolipidemic agents;
thiazolidinediones(TZDs),whichbindtoPPARγ,areinsulin
sensitizers. A recent report shows that retinoic acid, depend-
ing on the ratio of cellular retinoic acid binding protein 2
(CRABP-II) and fatty acid binding protein 5 (FABP5), may
function as a PPARδ ligand [16].
3. BIOLOGICAL FUNCTIONS OF PPARδ
The roles of PPARα and PPARγ in energy homeostasis
are relatively easy to understand because the former is
predominantly expressed in the brown adipose tissue and
liver, and the latter, the adipose tissue [8, 17]. While PPARα
catabolizes lipid in the liver, PPARγ facilitates fatty acid
storage in adipose tissue by inducing the maturation of
preadipocyte to fat cells.
The functions of PPARδ, on the other hand, are not as
easy to ascertain because PPARδ has a ubiquitous distribu-
tion (including high levels of expression in the gut, kidney,
and heart, and a lower level of expression in the liver) and
interacts with extensive arrays of proteins in the cells (more
in Section 2). Reported functions of PPARδ include the
formation of intestinal adenoma [18]a n dc o l o nc a n c e r[ 19],
the healing of skin [20], the development of hair follicles
[21], and the protection of cells against noxious stimuli
[10, 22]. The reproductive function of PPARδ was revealed
for the ﬁrst time during the investigation of cyclooxygenase-
2 knockout mouse [23].
4. PPARδ AND REPRODUCTION
Inprimates,includinghumans,matureeggsarepickedupby
theﬁmbriaandbecomefertilizedintheampulla.Thezygotes
remain in the oviduct for 72 hours; develop to morula/early
blastocyst stage embryos before entering into the uterus.
During this period, the oviduct produces soluble factors to
promote embryo development and protect the embryo.
As mentioned earlier, the link between PPARδ and
reproduction was ﬁrst revealed at the implantation site of
cyclooxygenase-2 knock out mice [23]. Since then, it was
learned that embryos express PPARδ and that oviducts
and embryos produce PGI2. Recent studies also show that
exogenous PPARδ ligand promotes the development of
embryos and enhances their implantation potential (more in
Section 4.4).Jaou-Chen Huang 3
4.1. Femalereproductivetractandembryos
producePPARδ ligand
We analyzed the metabolites of arachidonic acid by human
[24]a n dm o u s e[ 25] oviducts and found substantial amount
of PGI2. Further analysis shows that PGI2 production by the
oviducts varies according to the estrus cycle. It peaks shortly
after ovulation, coincides with the presence of cleaving
zygotes in the oviduct and the “window” of embryonic
responsiveness to PGI2 [25]. Oviducts posses PGI2 synthase
and cyclooxygenase-2; the latter is the rate limiting enzyme
of PG synthesis. The increased PGI2 production is due to
upregulation of the cyclooxygenase-2 gene. Oviduct also
produces retinoic acid [26], the eﬀects of oviduct-derived
retinoicacidonembryodevelopmentiscontroversial(details
below).
Similartooviducts,embryosalsometabolizearachidonic
acid via cyclooxygenase and lipoxygenase pathways. PGI2
is the most abundant metabolites of arachidonic acid by
mouseembryos[27].PreimplantationembryosexpressPGI2
synthase, and cyclooxygenase-1 and -2; all are expressed in
early stage and throughout the preimplantation period. The
preimplantation embryos also produce retinoic acid [28]b u t
its role in embryo development is yet to be determined.
T h eu t e r u si sk n o w nt op r o d u c eP G I 2 [29]b u ti t sc e n t r a l
role in assisting embryo implantation was not revealed until
twenty years later [23]. The uterus produces retinoic acid
[30] but its biological role is unclear. Similarly, the ovary
produces retinoic acid [31]a n dP G I 2 [32] but the extent
to which they interact with PPARδ to inﬂuence oocyte
maturation is not clear.
4.2. TestesexpressPPARδ
All three PPAR isotypes are present in Sertoli and Leydig
cells of the testes: PPARα and -δ transcript and protein
a r ee x p r e s s e di nL e y d i gc e l l sa n dS e r t o l ic e l l so fr a t[ 33],
PPARγ1 transcript is detected in human testis [34], both
PPARα and -γ transcripts and proteins are expressed in
mouse Sertoli cells [35]. In addition, mouse spermatids
and spermatocytes express PPARδ [36]. The functionality
of PPARδ in the testes is supported by the presence of
Ssm,an o v e lP P A R δ target gene in mouse testes [37]. Thus
PPARδ maydirectlyorindirectly(i.e.,viaPPARαor-γ)aﬀect
spermatogenesis. Information regarding PPARδ expression
a n da c t i o ni nm a t u r es p e r m si sl i m i t e d .W ep r e vi o u s l yr e p o rt
that iloprost (a PGI2 analog) does not aﬀect sperm activity
[38]. However, the response of mature sperms to synthetic
PPARδ ligand or retinoic acid has not been reported.
4.3. OvariesexpressPPARδ
Similar to testes, the ovary expresses all three PPAR isotypes
[39]. While PPARδ is expressed throughout the ovary,
PPARα is mainly expressed in the theca and the stroma, and
PPARγ, in the granulosa cells (of human, pig, rodents, and
sheep) and the oocytes (of cattle and zebraﬁsh). Of the three
PPARisotypesintheovary,onlyPPARγ showscyclicchanges
thus implying its role in follicular genesis and/or oocyte
maturation. Since PPARδ may regulate the transcriptional
activity of PPARγ, the growth of follicles or oocytes may be
indirectly modulated by PPARδ ligand. The expression of
PPARδ and the eﬀect of its activation on the oocytes remain
unclear at the moment.
4.4. PreimplantationembryosexpressPPARδ
Compared with PPARγ [28, 40]o rP P A R α [28, 40], there is
more information regarding the expression of PPARδ and
the outcome of its activation on preimplantation embryos
[28,40].MouseembryosexpressPPARδ atanearlystage[40,
41] and throughout the preimplantation period. Blastocyst
stage embryos express PPARδ in the inner cell mass and
the trophectoderm [40]. PPARδ activation is associated
with embryonic cell proliferation and improved embryo
development [40]. Supplementing L-165,041 (a synthetic
PPARδ ligand) or iloprost (a PGI2 analog) to culture media
enhances embryo hatching [38, 40–42]. Pretreatment with
iloprost also increases the potentials of implantation and live
birth of mouse embryos [40, 43].
The reported eﬀects of retinoic acid on embryo develop-
ment are inconclusive: some show it is beneﬁcial to embryo
development [44, 45], others show it is detrimental [46, 47].
A recent report shows LG100268 (a synthetic RXR ligand)
reduces trophectoderm cell proliferation in a concentration-
dependent manner, but enhances the development of bovine
blastocysts at 0.1μM[ 48]. Since retinoic acid binds to
retinoic acid receptor (RAR), RXR, and (depending on the
balance of intracellular CRABP-II and FABP5) PPARδ, the
eﬀect of retinoic acid on embryo development is likely to
depend on its concentration as well as receptor availability.
The latter is likely to change according to the developmental
stage of the embryo. More studies are needed to resolve this
complex issue.
5. CLINICALAPPLICATIONSOFPPARδ LIGANDINART
PPARδ can be activated via one of the three methods: PGI2
(either stable analog or natural PGI2), synthetic PPARδ
ligand, or retinoic acid. The data presented above supports
the notion that embryonic PPARδ activation by iloprost or
synthetic PPARδ ligand may enhance ART outcome. How-
ever, using PPARδ ligand in ART should be approached with
caution. A PPARδ ligand suitable for ART use should have
passed extensive reproductive toxicology studies involving
laboratory animals as well as domestic species to assure
the health of progeny. The potential applications of PPARδ
ligand in ART are listed below.
5.1. UsingPPARδ ligandtoenhancegametefunction
The potential of PPARδ ligand in enhancing male gamete
function or production is unknown because there is limited
information on the eﬀects of PPARδ ligand on the sper-
matogenesis and sperm activities. PPARδ may have no eﬀect
on sperm function because PGI2 analog does not seem to
aﬀect the motility of human sperms [38]. However, synthetic4 PPAR Research
PPARδ ligand or retinoic acid was not tested in the previous
report.
It is not clear the extent to which PPARδ ligand aﬀects
the oocytes either directly or indirectly (through granulosa
cells). At the molecular level, PPARδ ligand has the potential
to inﬂuence follicular genesis and/or oocyte maturation via
PPARδ or PPARγ. This inﬂuence depends on the species-
speciﬁc expression of PPARγ and PPARδ in the oocytes and
the granulosa cells [39]. Recent reports show PPARγ ligand
enhances the meiotic resumption of mouse oocytes [49]a n d
reverses the adverse eﬀects of diet-induced obesity on the
oocytes [50]. More research is needed to understand the
potential targets of PPARδ ligand in the ovary, that is, oocyte
versus granulosa cells and PPARδ versus PPARγ.
5.2. UsingPPARδ ligandtoenhance
embryodevelopment
Three independent laboratories using diﬀerent strains of
mice show iloprost (a PGI2 analog) enhances embryo
development [10, 38, 41]. A recent report, based on 60
cryopreserved human embryos donated by patients for
research, conﬁrmed the enhancing eﬀects of iloprost on
human embryos [51]. Mouse embryos previously exposed to
iloprost produce more implantation sites and yield more live
pups [43]. These positive ﬁndings support the use of PPARδ
ligand to enhance IVF outcome.
Whereas no synthetic PPARδ ligand has been approved
by the FDA for clinical use, iloprost (which activates PGI2
receptor and PPARδ) is approved by the FDA to treat
pulmonary hypertension and peripheral vascular disease.
Iloprost has undergone rigorous toxicology test and shows
no teratogenicity [52]. Various animals (including rats,
rabbit, and monkeys) exposed to iloprost during the peri-
implantation period and throughout the pregnancy produce
normal oﬀspring. Based on four positive results from inde-
pendent sources (three involving mouse embryos and one
involving human embryo described above) and reassuring
reproductive toxicology proﬁle, a small scale, phase I/II
clinical trial using iloprost may be considered. Supple-
menting iloprost to IVF embryos mimics the environment
of the oviduct which provides a PGI2 rich environment
surrounding the embryos [24, 25].
There is a long way before retinoic acid is ready for
use in ART. Given that PPARδ activation by retinoic acid is
dependent on the ratio of CRABP-II and FABP5, the extent
to which retinoic acid functions as a PPARδ ligand in the
embryos is likely to vary based on the developmental stage of
the embryos. More research is needed to ascertain the stage-
dependent response of embryos to retinoic acid.
5.3. UsingPPARδ ligandtoaugmentPPARδ system
attheimplantationsite
The uterus, being the site of implantation, is as important
as the embryos in ensuring a good ART outcome. Therefore,
although uterus is not an area served by ART, a discussion
about PPARδ ligand and ART is not complete without a brief
discussion of the uterus.
It is PPARδ at the implantation site that establishes
the ﬁrst link between PPAR and reproduction [23]. Recent
evidence suggests that a host of signaling pathways involved
in decidualization, implantation, and placentation converge
on PPARδ:m a t e r n a lP P A R δ is important for decidualiza-
tion and implantation; embryonic PPARδ is important for
placentation [53]. Thus enhancing the PPARδ system of
the uterus may be a novel method to ensure ART success.
Activating PPARδ system at the implantation site is diﬀer-
ent from activating PPARδ system in the preimplantation
embryos. The former involves administering PPARδ ligand
to potential mothers during the peri-implantation period;
the latter involves exposing IVF embryos to PPARδ ligand
prior to embryo transfer. The former may require days of
treatment; the latter only takes 18–24 hours (i.e., during
the eight cell to morular stage transition). In addition,
moreinformationregardinggenesandpathwaysactivatedby
PPARδ ligand in the uterus and their impacts on the progeny
needstobeobtainedbeforeitcanbeusedtotargettheuterus.
5.4. UsingPPARδ ligandtoimproveoocyte
cryopreservationoutcome
One important aspect of ART is the cryopreservation of
oocytes. Oocyte cryopreservation is considered as a solution
to ovarian aging in women who wish to defer raising
their family; it is also viewed as one of the methods
to preserve fertility in young women who are about to
receivechemotherapyorirradiation.Theoutcomeofoocytes
cryopreservation is, however, far from satisfactory [54]; its
success is hampered by freezing injury [55]. Lipid in the
egg membrane and inside the cytoplasm is believed to
be one of the contributing factors. Modifying membrane
lipid [56] or removing excess cytoplasmic lipid [57]r e p o r t -
edly enhances oocyte survival after cryopreservation. Since
PPARδ regulates lipid metabolism, it may mobilize lipid and
augment the viability and the developmental competence of
cryopreserved oocytes. The suitability of the above method
in human ART requires more research because lipid content
in the oocytes varies among species [58].
6. SUMMARY
Competent gametes, quality embryos, and a receptive
endometrium are essential elements for a viable pregnancy.
The outcome of ART may thus be enhanced by improving
any or all of the above elements. While it is high time to
consider using PPARδ ligand such as iloprost to enhance
embryo development, the application of PPARδ ligand in
other areas of ART requires more research. Continuing
research on the reproductive functions of PPARδ and the
safety of its ligand will ensure a smooth translation of basic
science to clinical medicine.
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